Published in PLoS One on June 08, 2010
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother (2011) 1.46
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med (2013) 1.29
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol (2013) 1.16
Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res (2013) 1.04
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer (2014) 0.87
Effects of 4-1BB signaling on the biological function of murine dendritic cells. Oncol Lett (2011) 0.84
Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother (2011) 0.81
Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. Oncoimmunology (2014) 0.81
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. Oncoimmunology (2015) 0.78
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc Natl Acad Sci U S A (2015) 0.77
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects. Cancer Immunol Res (2016) 0.75
Soluble expression of recombinant human CD137 ligand in Escherichia coli by co-expression of chaperones. J Ind Microbiol Biotechnol (2011) 0.75
Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung. Mucosal Immunol (2017) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
T cell receptor antagonist peptides induce positive selection. Cell (1994) 18.66
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol (2001) 9.23
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature (1989) 7.52
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol (2001) 6.78
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
Early programming of T cell populations responding to bacterial infection. J Immunol (2000) 4.57
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest (2001) 4.37
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature (2001) 3.99
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med (2007) 3.07
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol (1998) 2.11
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol (2002) 2.05
Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol (1999) 1.95
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood (2009) 1.81
Immune responses in 4-1BB (CD137)-deficient mice. J Immunol (2002) 1.74
Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol (2002) 1.65
Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol (1997) 1.62
IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol (2006) 1.58
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol (2007) 1.57
Initial antigen encounter programs CD8+ T cells competent to develop into memory cells that are activated in an antigen-free, IL-7- and IL-15-rich environment. J Immunol (2004) 1.54
Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol (2007) 1.52
Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol (2002) 1.51
CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med (2010) 1.48
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol (2002) 1.29
Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 1.27
Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res (2009) 1.26
CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood (2007) 1.25
The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev (2008) 1.22
Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res (2004) 1.22
NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer (2004) 1.17
Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol (2009) 1.16
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther (2004) 1.10
A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine (2009) 1.09
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol (2009) 1.09
Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy. Cancer Res (2008) 1.08
Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. J Natl Cancer Inst (2000) 1.07
4-1BB functions as a survival factor in dendritic cells. J Immunol (2009) 1.05
CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood (2010) 1.03
Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol (2005) 0.99
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood (2009) 0.99
Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res (1998) 0.96
Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha. J Leukoc Biol (2001) 0.93
Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol (2004) 0.93
A role for perforin in activation-induced cell death. J Immunol (1998) 0.86
Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci (2007) 0.85
If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine. J Exp Med (2007) 0.82
LPS/TLR4 signal transduction pathway. Cytokine (2008) 6.60
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev (2003) 3.79
Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature (2002) 3.74
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell (2011) 3.61
Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol (2004) 3.33
Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol (2010) 3.27
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol (2003) 3.18
Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med (2008) 3.10
4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med (2004) 3.01
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med (2005) 2.67
Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med (2003) 2.62
Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev (2009) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med (2009) 2.26
iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science (2012) 2.14
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol (2002) 2.05
Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med (2003) 2.04
Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A (2011) 1.98
TCR affinity and negative regulation limit autoimmunity. Nat Med (2004) 1.94
Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med (2009) 1.78
Vav1 controls integrin clustering and MHC/peptide-specific cell adhesion to antigen-presenting cells. Immunity (2002) 1.77
Essential role for caspase-8 in Toll-like receptors and NFkappaB signaling. J Biol Chem (2007) 1.66
Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood (2006) 1.65
Shp1 regulates T cell homeostasis by limiting IL-4 signals. J Exp Med (2013) 1.64
TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest (2007) 1.63
Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J Exp Med (2011) 1.60
IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol (2006) 1.58
Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages. Nat Immunol (2007) 1.57
4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol (2003) 1.54
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48
CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc Natl Acad Sci U S A (2008) 1.48
Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. Nat Immunol (2003) 1.45
Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol (2008) 1.42
Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine (2005) 1.40
TNF family ligands define niches for T cell memory. Trends Immunol (2007) 1.38
Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol (2005) 1.38
Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. J Immunol (2009) 1.38
TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J (2004) 1.33
Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice. Hepatology (2010) 1.33
4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol (2004) 1.30
A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol (2004) 1.28
Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 1.27
Caspase-3-dependent beta-cell apoptosis in the initiation of autoimmune diabetes mellitus. Mol Cell Biol (2005) 1.26
CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation (2010) 1.26
The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo. J Exp Med (2002) 1.24
Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol (2005) 1.23
ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J Immunol (2008) 1.23
Role of T cell costimulation in anti-viral immunity. Semin Immunol (2004) 1.23
CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol (2004) 1.22
CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J Exp Med (2002) 1.22
Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol (2006) 1.21
4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol (2002) 1.21
Role of ICOS versus CD28 in antiviral immunity. Eur J Immunol (2002) 1.20
Involvement of Toso in activation of monocytes, macrophages, and granulocytes. Proc Natl Acad Sci U S A (2013) 1.19
Immunotherapy of cancer with 4-1BB. Mol Cancer Ther (2012) 1.19
Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol Cell Biol (2006) 1.18
CD4+ and CD8+ T cell survival is regulated differentially by protein kinase Ctheta, c-Rel, and protein kinase B. J Immunol (2007) 1.18
T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev (2011) 1.17
Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest (2007) 1.17
Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur J Immunol (2004) 1.17
Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol (2009) 1.16
A critical role for the innate immune signaling molecule IRAK-4 in T cell activation. Science (2006) 1.16
Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J Immunol (2005) 1.15
PKCtheta signals activation versus tolerance in vivo. J Exp Med (2004) 1.15
Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood (2005) 1.14
Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood (2004) 1.13
4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine (2006) 1.13
GSK3: an in-Toll-erant protein kinase? Nat Immunol (2005) 1.11
A critical role for TNF receptor-associated factor 1 and Bim down-regulation in CD8 memory T cell survival. Proc Natl Acad Sci U S A (2006) 1.10
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J Clin Invest (2012) 1.10
Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med (Berl) (2006) 1.09
Natural killer cells regulate diverse T cell responses. Trends Immunol (2013) 1.09
Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res (2012) 1.09
Hematopoietic cell-derived interferon controls viral replication and virus-induced disease. Blood (2008) 1.09
NF-kappaB couples protein kinase B/Akt signaling to distinct survival pathways and the regulation of lymphocyte homeostasis in vivo. J Immunol (2005) 1.08
4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation. J Immunol (2008) 1.08
CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol (2010) 1.08
Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res (2007) 1.08
The inducible costimulator plays the major costimulatory role in humoral immune responses in the absence of CD28. J Immunol (2004) 1.08
4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur J Immunol (2003) 1.06
DNA damage- and stress-induced apoptosis occurs independently of PIDD. Apoptosis (2009) 1.05
Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J Immunol (2003) 1.05
Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett (2009) 1.05
4-1BB functions as a survival factor in dendritic cells. J Immunol (2009) 1.05
TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR. J Immunol (2003) 1.05
Accessory protein-like is essential for IL-18-mediated signaling. J Immunol (2005) 1.05